A Study of 1018 Immunostimulatory Sequence (ISS) Administered With Irinotecan and Cetuximab to Treat Patients With Previously Treated Metastatic Colorectal Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1

Total Enrollment

14 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-11-30

Study Completion Date

2007-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main objectives of this study are to establish a safe, tolerable and active dose of 1018 ISS administered in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer. Other objectives also include determining tumor response, time to disease progression, and overall survival in treated patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Sequential Treatment Strategy for Metastatic Colorectal Cancer

NCT01878422

Metastatic Colorectal Cancer

COMPLETED PHASE3

Irinotecan and Cetuximab for Colorectal Cancer as Second Line Therapy

NCT00336856

Colon Cancer Rectum Cancer

COMPLETED PHASE2

A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer

NCT00478634

Colorectal Cancer Colorectal Carcinoma Colorectal Tumors +1 more

COMPLETED PHASE1

Rechallenge of Cetuximab Combined With Irinotecan as Third-line Chemotherapy in Patients With Metastatic Colorectal Cancer - Phase II Study

NCT02316496

Colorectal Cancer Metastatic

TERMINATED PHASE2

Cetuximab Plus Irinotecan in Colorectal Cancer Patients Who Progressed After Failure With Cetuximab Plus Irinotecan

NCT01004159

Colorectal Cancer

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a Phase I, open-label study of escalating dose levels of 1018 ISS in combination with irinotecan and cetuximab in patients with previously treated metastatic colorectal cancer. Approximately 15 patients will be treated. The objectives of this study are to establish a safe, tolerable, and active dose of 1018 ISS, determine tumor response, time to disease progression, and overall survival in treated patients.

The safety and tolerability of 1018 ISS will be evaluated by periodic laboratory assessments, physical examinations, and compilation of adverse events.

Once study patients have been consented, screened, and assigned to one of the dose levels of 1018 ISS, patients will receive two 4 week cycles of 1018 ISS therapy plus irinotecan every other week and cetuximab weekly. Irinotecan and cetuximab will continue thereafter until disease progression, unacceptable toxicity, or until the patient refuses treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Low dose of 1018 ISS

Group Type EXPERIMENTAL

1018 ISS immunostimulatory oligonucleotide

Intervention Type DRUG

6 weekly subcutaneous (under the skin) injections

2

Middle dose of 1018 ISS

Group Type EXPERIMENTAL

1018 ISS immunostimulatory oligonucleotide

Intervention Type DRUG

6 weekly subcutaneous (under the skin) injections

3

High dose of 1018 ISS

Group Type EXPERIMENTAL

1018 ISS immunostimulatory oligonucleotide

Intervention Type DRUG

6 weekly subcutaneous (under the skin) injections

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

1018 ISS immunostimulatory oligonucleotide

6 weekly subcutaneous (under the skin) injections

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Signed, written, informed consent must be obtained from the patient or their legal representative before any study-specific procedures are performed
* Confirmed diagnosis of adenocarcinoma of the colon or rectum not amenable to curative surgery
* One or more prior systemic therapy regimens for metastatic cancer which must have included a fluoropyrimidine (5-fluorouracil (FU) by infusion or capecitabine), oxaliplatin or irinotecan with or without bevacizumab

Exclusion Criteria

* Clinically significant obstructive symptoms, intestinal bleeding, or chronic or recent acute gastrointestinal disorder with diarrhea as a major symptom
* History of unstable or deteriorating cardiovascular or cerebrovascular disease within 3 months before the first dose of protocol therapy
* Clinical evidence of brain metastases or central nervous system disease
* Pregnant or lactating women
* Serious medical or psychiatric illness
* Malignancy other than colorectal carcinoma within the past 2 years, except curatively treated, superficial skin cancer or carcinoma in situ of the cervix
* Patients who have been on any experimental study or anti-tumor therapy, received radiotherapy, or had prior surgery (except venous access device placement) within 28 days before the first dose of protocol therapy

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No